JPRN-jRCT2080222028未知2 期
A Randomized, Open-label, Two-arm Phase II Trial Comparing the Efficacy of Sequential Ipilimumab Versus Best Supportive Care Following First-line Chemotherapy in Subjects With Unresectable Locally Advanced/Metastatic Gastric or Gastro-esophageal Junction Cancer
Bristol-Myers K.K.0 个研究点目标入组 114 人开始时间: 2013年2月20日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 114
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Histologically confirmed, unresectable locally advanced or metastatic adenocarcinoma of the gastric and gastro-esophageal junction
- •- Received first-line chemotherapy using fluoropyrimidine and platinum combination without disease progression
- •- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •- Measurable disease by modified WHO criteria (unless complete response for previous chemotherapy)
排除标准
- •- Known Human Epidermal growth factor Receptor2 (HER2) positive status
- •- Radiological evidence of brain metastases
- •- History of severe autoimmune or immune mediated disease requiring prolonged immunosuppressive treatment
- •- Inadequate hematologic, renal and hepatic function
研究者
相似试验
进行中（未招募）
不适用
An efficacy study in gastric and gastroesophageal junction cancer comparing ipilimumab versus standard of care immediately following first line chemotherapyocally advanced (unresectable) or metastatic adenocarcinoma of the gastric and gastro-esophageal junctionMedDRA version: 16.0Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.0Level: PTClassification code 10030137Term: Oesophageal adenocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-000853-22-DEBristol-Myers Squibb International Corporation152
进行中（未招募）
不适用
An efficacy study in gastric and gastroesophageal junction cancer comparing ipilimumab versus standard of care immediately following first line chemotherapyEUCTR2011-000853-22-ESBristol-Myers Squibb International Corporation152
进行中（未招募）
不适用
An efficacy study in gastric and gastroesophageal junction cancer comparing ipilimumab versus standard of care immediately following first line chemotherapyocally advanced (unresectable) or metastatic adenocarcinoma of the gastric and gastro-esophageal junctionMedDRA version: 15.0Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 15.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 15.0Level: PTClassification code 10030137Term: Oesophageal adenocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-000853-22-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO152
进行中（未招募）
不适用
A Phase 2b Open-label, Randomized, Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Relapsed/Refractory DLBCLMedDRA version: 17.1Level: HLTClassification code 10012819Term: Diffuse large B-cell lymphomasSystem Organ Class: 100000004851EUCTR2014-001977-15-ESKaryopharm Therapeutics, Inc.200
招募中
2 期
A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)2024-512115-50-00Karyopharm Therapeutics Inc.30